The Wall Street Transcript
The Wall Street Transcript - In-Depth Interviews for Investors
Healthcare >> CEO Interviews >> November 12, 2023

Interview with the Chairman and CEO: Inozyme Pharma Inc. (NASDAQ:INZY)

Treco, Douglas
Douglas Treco, Ph.D., is CEO and board chairman at Inozyme Pharma Inc. (INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of severe conditions affecting the vasculature, soft tissue, and skeleton. Among his previous accomplishments, Dr. Treco co-founded Transkaryotic Therapies, Inc., which produced a number of rare disease drugs. He was also co-founder, president, and CEO of Ra Pharmaceuticals, which was acquired in April 2020 by UCB S.A. for $2.5 billion. Zilucoplan, Ra’s lead program for the treatment of myasthenia gravis, is currently under review for marketing approval in the United States and European Union. A molecular biologist by training, Dr. Treco has long dedicated himself to pioneering solutions in rare disease therapeutics. He was previously a visiting scientist in the Department of Molecular Biology at Massachusetts General Hospital and a lecturer in genetics at Harvard Medical School from 2004 to 2007. He holds a B.A. in Biology from the University of Delaware, a Ph.D. in Biochemistry and Molecular Biology from the State University of New York at Stony Brook, and performed post-doctoral research at the Salk Institute for Biological Studies and Massachusetts General Hospital. Profile
Word count: 3,301

TWST: We can get started. Let’s start with an overview of the company, its history, and some milestone achievements.

Dr. Treco: Inozyme was

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
Walmart Inc.
International Business Machines Corporation
Citigroup Inc.
Exxon Mobil Corporation
Bank of America Corporation
Dell Inc.
Verizon Communications Inc.
Alphabet Inc

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS
Interview with the CEO: Pasithea Therapeutics Corp. (NASDAQ:KTTA)
Interview with the CEO: BetterLife Pharma Inc. (OTCMKTS:BETRF)
Interview with the CEO: Cansortium Inc. (OTCMKTS:CNTMF)
SECTOR ROUNDTABLES
Natural Gas Weighs Heavy On E&P Near-Term Prospects
Roundtable Forum:optimism Despite Uncertainty In For-profit Education
Roundtable Forum:a Shift In Focus To Natural Gas From Oil
MONEY MANAGER INTERVIEWS
AI Opportunities Expand to Industrial, Utilities and Energy Sectors
India Fund Manager Expects Discretionary Spending to Grow
Inefficiency in Ex-US Markets Creates Opportunity to Buy at a Discount
ANALYST INTERVIEWS
Five Companies Dominate in Psychedelics-Based Drug Development
Cidara’s Long-Acting Antiviral Drug Could Be a Game Changer
Spotting Potential in the High-Risk, High Reward Neuroscience Space
Since 1963
© The Wall Street Transcript 2016, 2024
Terms and Conditions
Privacy Policy